

2025 PQA Annual Meeting

May 19 -21, 2025 / Tampa, FL

Jointly provided by Partners for Advancing Clinical Education and Pharmacy Quality Alliance (PQA)

Instructions for Credit

To receive CE credit, learners must follow these steps after their participation in each session:

1. Visit <https://cme.partnersed.com/PQA2025>
2. Select the session attended
3. Login
4. Complete the activity evaluation
5. Upon completion of all evaluation questions, your credit will be submitted to CPE Monitor.
Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Target Audience

This activity is intended for pharmacists.

Educational Objectives

Upon completion of this activity, participants should be able to:

- Describe real-world examples of promising practices to improve medication use quality
- Explain how social drivers of health, health equity, and the patient voice can be integrated into medication use services
- Discuss examples of value-based payment models that include medication use services and options for improving their execution
- Outline quality improvement strategies that can be used to improve medication use quality

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

The following faculty have the following relevant financial relationships:

Brooke Looney – Researcher: AstraZeneca, Pfizer

Stephanie White – Researcher: AstraZeneca, BeiGene, Pfizer

All other faculty have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and PQA. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy Continuing Education

Partners designates this continuing education activity for 4.0 contact hour(s) (0.4 CEUs) of the Accreditation Council for Pharmacy Education.

Type of Activity: Knowledge

Concurrent Sessions/Universal Activity Numbers:

Tuesday 5/20/2025 - 10:30 - 11:30 am Concurrent Sessions; 1.0 contact hour

- A Rising Tide Lifts All Boats: The Minnesota Model for MTM Services
JA4008073-9999-25-161-L04-P
- Driving Impactful Change: Integrating SDoH Initiatives into Pharmacy Workflows and Programs
JA4008073-9999-25-162-L04-P
- Improving Pharmacy Quality, Health Outcomes, and Patient Experience Through Health Plan and Pharmacy Value-Based Partnerships
JA4008073-9999-25-163-L04-P
- Key Elements of Practice Redesign in Community Pharmacies
JA4008073-9999-25-164-L04-P

Tuesday 5/20/2025 - 11:45 - 12:45 pm Concurrent Sessions; 1.0 contact hour

- Addressing Social Barriers to Improve Medication Adherence and Address Health Equity Index
JA4008073-9999-25-165-L04-P
- Development and Implementation of a Novel Pharmacist-Led MedAdherence Program Utilizing the PQA Medication Therapy Problem (MTP) Framework
JA4008073-9999-25-166-L04-P
- First Look: Effects of the Medicare Out-of-Pocket Cost Cap on Persistence to Basal Insulin
JA4008073-9999-25-167-L04-P
- Improving Cholesterol Management via Data-Driven Team-Based Care Solutions in an FQHC Setting
JA4008073-9999-25-168-L04-P

Tuesday 5/20/2025 – 2:15 – 3:15 pm Concurrent Sessions; 1.0 contact hour

- A Multi-year Evaluation of Patient Experience and Quality in a Marketplace MTM Program
JA4008073-9999-25-169-L04-P
- Advancing Health Equity and Medication Adherence: Harnessing Behavioral Science for Quality Improvement on Social Risk Factors
JA4008073-9999-25-170-L04-P
- Empowering Oncology Care: The Critical Role of Pharmacists in Quality Improvement Initiatives
JA4008073-9999-25-171-L04-P

Wednesday 5/21/2025 – 2:15 – 3:15 pm Concurrent Sessions; 1.0 contact hour

- Applying Recommendations for Health Plans and Pharmacists to Advance Coverage of Pharmacists' Services in the Medical Benefits
JA4008073-9999-25-172-L04-P
- Diabetes Chronic Condition Management and Medical Billing: A Collaboration between a Health Plan and Community Pharmacies
JA4008073-9999-25-173-L04-P
- Improving Medication Safety Through Pharmacy Reimbursement for At Home Drug Disposal Solution
JA4008073-9999-25-174-L05-P

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.